Vol 53 No 09

"Based on this proposal, some shifts may significantly impact the practice of urology," write Jonathan Rubenstein, MD, and Mark Painter.

We recap notable headlines from last month in the benign urology space.

Christopher Weight, MD, MS, discusses the current state and directions of AI and prostate cancer.

HIFU was shown to be an effective and tolerable treatment option for patients with intermediate-risk localized prostate cancer.

The target action date for the application is March 6, 2026.

The phase 1 STRIKE-001 trial will evaluate KTX-2001 as both a monotherapy and in combination with darolutamide.

FX-909 is an investigational small molecule PPARG inhibitor for patients with locally advanced or metastatic urothelial carcinoma.

Five-year data from the phase 3 KEYNOTE-426 trial confirm the clinical benefits of front-line pembrolizumab plus axitinib in advanced ccRCC.

INKmune was well-tolerated across all 3 dose levels assessed.

Enzalutamide plus ADT was associated with significant improvements in rPFS and time to castration resistance compared with darolutamide plus ADT.

The 500 mg regimen of abiraterone acetate demonstrated comparable anti-tumor activity and a favorable safety profile compared with the standard 1000 mg dose.

However, M-HoLEP was superior in terms of enucleation time and efficiency, catheterization time, and hospital stay.

Data from the phase 3b study were recently published in Reviews in Urology, showing that administration of mitomycin intravesical solution in the home setting was feasible, safe, and effective.

MRWS was shown to prolong the time off systemic therapy and was associated with favorable tolerability.